HEADER TRANSFERASE 22-JUL-15 5A9U TITLE STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX TITLE 2 WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-2,10,16-TRIMETHYL- 15-OXO- TITLE 3 10,15,16,17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4,3-H)(2,5,11) TITLE 4 BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE). COMPND MOL_ID: 1; COMPND 2 MOLECULE: ALK TYROSINE KINASE RECEPTOR; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: TYROSINE KINASE DOMAIN, RESIDUES 1093-1411; COMPND 5 SYNONYM: ANAPLASTIC LYMPHOMA KINASE; COMPND 6 EC: 2.7.10.1; COMPND 7 ENGINEERED: YES; COMPND 8 MUTATION: YES; COMPND 9 OTHER_DETAILS: NONPHOSPHORYLATED SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 8 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS KEYWDS TRANSFERASE, RECEPTOR TYROSINE KINASE, ANAPLASTIC LYMPHOMA KINASE, KEYWDS 2 INHIBITOR, MUTANT EXPDTA X-RAY DIFFRACTION AUTHOR M.MCTIGUE,Y.-L.DENG,W.LIU,A.BROOUN,A.STEWART REVDAT 4 10-JAN-24 5A9U 1 REMARK REVDAT 3 08-MAY-19 5A9U 1 REMARK REVDAT 2 12-OCT-16 5A9U 1 REMARK HET HETNAM FORMUL REVDAT 2 2 1 HETATM REVDAT 1 08-JUN-16 5A9U 0 JRNL AUTH A.T.SHAW,L.FRIBOULET,I.LESHCHINER,J.F.GAINOR,S.BERGQVIST, JRNL AUTH 2 A.BROOUN,B.J.BURKE,Y.DENG,W.LIU,L.DARDAEI,R.L.FRIAS, JRNL AUTH 3 K.R.SCHULTZ,J.LOGAN,L.P.JAMES,T.SMEAL,S.TIMOFEEVSKI, JRNL AUTH 4 R.KATAYAMA,A.J.IAFRATE,L.LE,M.MCTIGUE,G.GETZ,T.W.JOHNSON, JRNL AUTH 5 J.A.ENGELMAN JRNL TITL RESENSITIZATION TO CRIZOTINIB BY THE LORLATINIB ALK JRNL TITL 2 RESISTANCE MUTATION L1198F. JRNL REF N.ENGL.J.MED. V. 374 54 2016 JRNL REFN ISSN 0028-4793 JRNL PMID 26698910 JRNL DOI 10.1056/NEJMOA1508887 REMARK 2 REMARK 2 RESOLUTION. 1.60 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2005 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.60 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 38.64 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1121081.140 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.8 REMARK 3 NUMBER OF REFLECTIONS : 41674 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.216 REMARK 3 R VALUE (WORKING SET) : 0.215 REMARK 3 FREE R VALUE : 0.258 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 3.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1253 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.007 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.2160 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.2150 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.258 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 3.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 1253 REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : 0.0070 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 41674 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.60 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.70 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 100.0 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 6645 REMARK 3 BIN R VALUE (WORKING SET) : 0.2890 REMARK 3 BIN FREE R VALUE : 0.3220 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 2.80 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 194 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.023 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2312 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 30 REMARK 3 SOLVENT ATOMS : 198 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 26.80 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 34.20 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -2.42000 REMARK 3 B22 (A**2) : -5.97000 REMARK 3 B33 (A**2) : 8.39000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.20 REMARK 3 ESD FROM SIGMAA (A) : 0.19 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.24 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.18 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.004 REMARK 3 BOND ANGLES (DEGREES) : 0.800 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 18.90 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.680 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.350 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.220 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.090 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.170 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.39 REMARK 3 BSOL : 51.54 REMARK 3 REMARK 3 NCS MODEL : NONE REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARA REMARK 3 PARAMETER FILE 2 : DNA-RNA_REP.PARA REMARK 3 PARAMETER FILE 3 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : ION.PARAM REMARK 3 PARAMETER FILE 5 : UNL.PARAM REMARK 3 PARAMETER FILE 6 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : DNA-RNA.TOP REMARK 3 TOPOLOGY FILE 3 : WATER.TOP REMARK 3 TOPOLOGY FILE 4 : ION.TOP REMARK 3 TOPOLOGY FILE 5 : UNL.TOP REMARK 3 TOPOLOGY FILE 6 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5A9U COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 22-JUL-15. REMARK 100 THE DEPOSITION ID IS D_1290064435. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 18-MAY-15 REMARK 200 TEMPERATURE (KELVIN) : 87 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : CLSI REMARK 200 BEAMLINE : 08ID-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9795 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH RAYONIX 300 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 42336 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.590 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 5.900 REMARK 200 R MERGE (I) : 0.06000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 43.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.59 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.65 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.9 REMARK 200 DATA REDUNDANCY IN SHELL : 5.60 REMARK 200 R MERGE FOR SHELL (I) : 0.92000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNX REMARK 200 STARTING MODEL: PDB ENTRY 4CLJ REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 41.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.10 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: HANGING DROP VAPOR DIFFUSION AT 13 REMARK 280 DEGREES C. 2 MICROLITERS OF PURIFIED PROTEIN SOLUTION (11-15 MG/ REMARK 280 ML) CONTAINING INHIBITOR COMPOUND AT A 2X STOICHIOMETRY OF REMARK 280 INHIBITOR TO PROTEIN WERE COMBINED WITH 2 MICROLITERS OF REMARK 280 SOLUTIONS CONTAINING: 0.2 M LITHIUM SULFATE, 17-21% PEG3350 AND REMARK 280 0.1M TRIS PH 7.6-8.5., PH 8.0, VAPOR DIFFUSION, HANGING DROP, REMARK 280 TEMPERATURE 286K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.87700 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 52.44350 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 28.79350 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 52.44350 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.87700 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 28.79350 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1085 REMARK 465 ALA A 1086 REMARK 465 HIS A 1087 REMARK 465 HIS A 1088 REMARK 465 HIS A 1089 REMARK 465 HIS A 1090 REMARK 465 HIS A 1091 REMARK 465 HIS A 1092 REMARK 465 GLY A 1125 REMARK 465 ALA A 1126 REMARK 465 PHE A 1127 REMARK 465 SER A 1136 REMARK 465 GLY A 1137 REMARK 465 MET A 1138 REMARK 465 PRO A 1139 REMARK 465 ASN A 1140 REMARK 465 ASP A 1141 REMARK 465 PRO A 1142 REMARK 465 SER A 1143 REMARK 465 ALA A 1280 REMARK 465 SER A 1281 REMARK 465 TYR A 1282 REMARK 465 TYR A 1283 REMARK 465 ARG A 1284 REMARK 465 LYS A 1285 REMARK 465 PRO A 1403 REMARK 465 LEU A 1404 REMARK 465 VAL A 1405 REMARK 465 GLU A 1406 REMARK 465 GLU A 1407 REMARK 465 GLU A 1408 REMARK 465 GLU A 1409 REMARK 465 LYS A 1410 REMARK 465 VAL A 1411 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLY A1402 CA C O REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA A1099 -122.80 56.42 REMARK 500 ARG A1248 -9.35 80.61 REMARK 500 ASP A1249 53.01 -148.73 REMARK 500 SER A1332 -8.63 83.43 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 5P8 A 2402 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 5AA8 RELATED DB: PDB REMARK 900 STRUCTURE OF C1156Y,L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE REMARK 900 IN COMPLEX WITH PF-06463922 ((10R)-7- AMINO-12-FLUORO-2,10,16- REMARK 900 TRIMETHYL-15-OXO-10,15, 16,17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4, REMARK 900 3-H)( 2,5,11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE). REMARK 900 RELATED ID: 5AA9 RELATED DB: PDB REMARK 900 STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN REMARK 900 COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12 -FLUORO-2,10,16- REMARK 900 TRIMETHYL-15-OXO-10,15,16,17- TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4, REMARK 900 3-H)(2,5, 11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE). REMARK 900 RELATED ID: 5AAA RELATED DB: PDB REMARK 900 STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN REMARK 900 COMPLEX WITH CRIZOTINIB REMARK 900 RELATED ID: 5AAB RELATED DB: PDB REMARK 900 STRUCTURE OF C1156Y,L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE REMARK 900 IN COMPLEX WITH CRIZOTINIB REMARK 900 RELATED ID: 5AAC RELATED DB: PDB REMARK 900 STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN REMARK 900 COMPLEX WITH CRIZOTINIB REMARK 999 REMARK 999 SEQUENCE REMARK 999 RESIDUES 1093-1411 OF HUMAN ANAPLASTIC LYMPHOMA KINASE REMARK 999 PLUS AN ENGINEERED N-TERMINAL HIS-TAG. RESIDUE CYS 1156 REMARK 999 IS MUTATED TO TYR. DBREF 5A9U A 1093 1411 UNP Q9UM73 ALK_HUMAN 1093 1411 SEQADV 5A9U MET A 1085 UNP Q9UM73 EXPRESSION TAG SEQADV 5A9U ALA A 1086 UNP Q9UM73 EXPRESSION TAG SEQADV 5A9U HIS A 1087 UNP Q9UM73 EXPRESSION TAG SEQADV 5A9U HIS A 1088 UNP Q9UM73 EXPRESSION TAG SEQADV 5A9U HIS A 1089 UNP Q9UM73 EXPRESSION TAG SEQADV 5A9U HIS A 1090 UNP Q9UM73 EXPRESSION TAG SEQADV 5A9U HIS A 1091 UNP Q9UM73 EXPRESSION TAG SEQADV 5A9U HIS A 1092 UNP Q9UM73 EXPRESSION TAG SEQADV 5A9U TYR A 1156 UNP Q9UM73 CYS 1156 ENGINEERED MUTATION SEQRES 1 A 327 MET ALA HIS HIS HIS HIS HIS HIS ASN PRO ASN TYR CYS SEQRES 2 A 327 PHE ALA GLY LYS THR SER SER ILE SER ASP LEU LYS GLU SEQRES 3 A 327 VAL PRO ARG LYS ASN ILE THR LEU ILE ARG GLY LEU GLY SEQRES 4 A 327 HIS GLY ALA PHE GLY GLU VAL TYR GLU GLY GLN VAL SER SEQRES 5 A 327 GLY MET PRO ASN ASP PRO SER PRO LEU GLN VAL ALA VAL SEQRES 6 A 327 LYS THR LEU PRO GLU VAL TYR SER GLU GLN ASP GLU LEU SEQRES 7 A 327 ASP PHE LEU MET GLU ALA LEU ILE ILE SER LYS PHE ASN SEQRES 8 A 327 HIS GLN ASN ILE VAL ARG CYS ILE GLY VAL SER LEU GLN SEQRES 9 A 327 SER LEU PRO ARG PHE ILE LEU LEU GLU LEU MET ALA GLY SEQRES 10 A 327 GLY ASP LEU LYS SER PHE LEU ARG GLU THR ARG PRO ARG SEQRES 11 A 327 PRO SER GLN PRO SER SER LEU ALA MET LEU ASP LEU LEU SEQRES 12 A 327 HIS VAL ALA ARG ASP ILE ALA CYS GLY CYS GLN TYR LEU SEQRES 13 A 327 GLU GLU ASN HIS PHE ILE HIS ARG ASP ILE ALA ALA ARG SEQRES 14 A 327 ASN CYS LEU LEU THR CYS PRO GLY PRO GLY ARG VAL ALA SEQRES 15 A 327 LYS ILE GLY ASP PHE GLY MET ALA ARG ASP ILE TYR ARG SEQRES 16 A 327 ALA SER TYR TYR ARG LYS GLY GLY CYS ALA MET LEU PRO SEQRES 17 A 327 VAL LYS TRP MET PRO PRO GLU ALA PHE MET GLU GLY ILE SEQRES 18 A 327 PHE THR SER LYS THR ASP THR TRP SER PHE GLY VAL LEU SEQRES 19 A 327 LEU TRP GLU ILE PHE SER LEU GLY TYR MET PRO TYR PRO SEQRES 20 A 327 SER LYS SER ASN GLN GLU VAL LEU GLU PHE VAL THR SER SEQRES 21 A 327 GLY GLY ARG MET ASP PRO PRO LYS ASN CYS PRO GLY PRO SEQRES 22 A 327 VAL TYR ARG ILE MET THR GLN CYS TRP GLN HIS GLN PRO SEQRES 23 A 327 GLU ASP ARG PRO ASN PHE ALA ILE ILE LEU GLU ARG ILE SEQRES 24 A 327 GLU TYR CYS THR GLN ASP PRO ASP VAL ILE ASN THR ALA SEQRES 25 A 327 LEU PRO ILE GLU TYR GLY PRO LEU VAL GLU GLU GLU GLU SEQRES 26 A 327 LYS VAL HET 5P8 A2402 30 HETNAM 5P8 (10R)-7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15, HETNAM 2 5P8 16,17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO[4,3-H][2,5, HETNAM 3 5P8 11]BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE FORMUL 2 5P8 C21 H19 F N6 O2 FORMUL 3 HOH *198(H2 O) HELIX 1 1 SER A 1104 LEU A 1108 5 5 HELIX 2 2 PRO A 1112 ILE A 1116 5 5 HELIX 3 3 SER A 1157 PHE A 1174 1 18 HELIX 4 4 LEU A 1204 THR A 1211 1 8 HELIX 5 5 ALA A 1222 ASN A 1243 1 22 HELIX 6 6 ALA A 1251 ARG A 1253 5 3 HELIX 7 7 PHE A 1271 ARG A 1279 1 9 HELIX 8 8 PRO A 1292 MET A 1296 5 5 HELIX 9 9 PRO A 1297 GLY A 1304 1 8 HELIX 10 10 THR A 1307 SER A 1324 1 18 HELIX 11 11 SER A 1334 SER A 1344 1 11 HELIX 12 12 PRO A 1355 TRP A 1366 1 12 HELIX 13 13 GLN A 1369 ARG A 1373 5 5 HELIX 14 14 ASN A 1375 ASP A 1389 1 15 HELIX 15 15 ASP A 1389 ASN A 1394 1 6 SHEET 1 AA 2 TYR A1096 PHE A1098 0 SHEET 2 AA 2 LYS A1101 SER A1103 -1 O LYS A1101 N PHE A1098 SHEET 1 AB 5 THR A1117 GLY A1121 0 SHEET 2 AB 5 VAL A1130 GLN A1134 -1 O GLU A1132 N ILE A1119 SHEET 3 AB 5 GLN A1146 LEU A1152 -1 O VAL A1147 N GLY A1133 SHEET 4 AB 5 ARG A1192 GLU A1197 -1 O ARG A1192 N LEU A1152 SHEET 5 AB 5 CYS A1182 SER A1186 -1 N ILE A1183 O LEU A1195 SHEET 1 AC 3 GLY A1202 ASP A1203 0 SHEET 2 AC 3 CYS A1255 LEU A1257 -1 N LEU A1257 O GLY A1202 SHEET 3 AC 3 ALA A1266 ILE A1268 -1 O LYS A1267 N LEU A1256 CISPEP 1 LEU A 1190 PRO A 1191 0 -4.55 SITE 1 AC1 14 LEU A1122 GLY A1123 VAL A1130 ALA A1148 SITE 2 AC1 14 LEU A1196 GLU A1197 MET A1199 ARG A1253 SITE 3 AC1 14 ASN A1254 LEU A1256 GLY A1269 ASP A1270 SITE 4 AC1 14 HOH A2073 HOH A2198 CRYST1 51.754 57.587 104.887 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019322 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017365 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009534 0.00000